Astellas/Cardiome’s Kynapid “Approvable”
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA is seeking additional safety information on Astellas/Cardiome's Kynapid (vernakalant) injection for the treatment of atrial fibrillation. The companies announced receipt of an FDA "approvable" letter for the NDA Aug. 11
You may also be interested in...
Astellas/Cardiome Schedule Kynapid Meeting With U.S. FDA
Cardiome's Oct. 9 investor update, announcing a Nov. 14 meeting with U.S. regulators on its/Astellas' Kynapid NDA, adds little clarity on how long the drug's approval process could be delayed
Astellas/Cardiome Schedule Kynapid Meeting With U.S. FDA
Cardiome's Oct. 9 investor update, announcing a Nov. 14 meeting with U.S. regulators on its/Astellas' Kynapid NDA, adds little clarity on how long the drug's approval process could be delayed
Astellas/Cardiome's Vernakalant Wins Advisory Committee Approval In 6-2 Vote
FDA's Cardiovascular and Renal Drugs Advisory Committee voted to approve Astellas Pharma/Cardiome's new drug application for its antiarrhythmic Kynapid (vernakalant hydrochloride injection) Dec. 11